Stirling-based Integrated Graphene, a technology development, and integration company, exploits a unique patented 3D graphene foam Gii®. It is a component that enables higher performing, lower cost, more sustainable products in multiple $trillion markets. The company just announced its plans to invest up to £8 million in scaling up its revolutionary Gii® manufacturing process.
The investment follows the significantly oversubscribed Series A+ funding round led by existing investors, Par Equity and Archangels (that invested in Earth Blox and PhysioMedics).
How will it use the funds?
The company’s investment plan will focus on scaling up the manufacturing of its market-ready graphene-enhanced electrodes and supercapacitors that are currently being piloted by global blue-chips in human diagnostics point of care testing and smart label asset tracking applications.
Integrated Graphene intends to double its existing footprint in Stirling and treble its headcount to 100 over the next three years, hiring a significant number of market-leading development and commercial experts in the UK, Europe, and North America. Also, it will increase capital expenditure in its next-generation pilot line to allow rapid market expansion of Gii-Sens and Gii-Cap.
Claus Marquordt, co-founder and CEO of Integrated Graphene said: “This investment marks a real tipping point for Integrated Graphene and the manufacturing of our unique 3D Graphene foam in its first two market-ready products. By investing now, we will be ready, this year, to produce millions of units per annum from a new facility in Stirling and to transfer the technology at scale to global partners in the future.”
Aidan MacMillan, Senior Investment Manager at Par Equity, said: “Integrated Graphene has developed a game changing, frontier solution with the potential to drive enormous impact across a range of large-scale industries. As existing investors in the business, Par Equity, and a selection of our advisers, have worked closely with Claus and the team to build the business. We’re delighted to continue our support in this round, to catalyse the team’s ambition and unlock the company’s growth potential.”
Niki Mckenzie, Joint Managing Director at Archangels, added: “Since we first invested in Integrated Graphene two years ago, the company has moved rapidly from start-up to scale-up and now has its sights focused on meeting increased global demand from multiple sectors. We are looking forward to continuing our relationship with the team, as they embark on this next critical phase of growth.”
Why Gii®?
Reports point out that the addressable market for graphene-enabled products is potentially more than $25 billion based on reasonable levels of penetration across all markets, and volume demand for graphene across key application markets is thought to have the potential to reach $1 trillion by 2030.
Founded in 2016 by Claus Marquordt and Marco Caffio in Stirling, Integrated Graphene emerged out of the stealth mode in 2020 and has developed the world’s only commercially viable graphene manufacturing process that is currently scaled to high volumes. This novel process eliminates the scaleup challenges associated with CVD graphene and graphene powder.
These printable electronic products include the Gii-Sens®, which offers a better and more-effective sensor material for the human diagnostics market and Gii-Cap® which targets 10% of $500 billion battery market, with the potential to remove 60 million batteries from being thrown away every year.
The company believes that its revolutionary Gii® manufacturing process addresses the key requirements of the graphene industry of producing high quality, cost effective and production scale graphene, which has not been achieved by any company to date.
